<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343146">
  <stage>Registered</stage>
  <submitdate>7/07/2011</submitdate>
  <approvaldate>14/07/2011</approvaldate>
  <actrnumber>ACTRN12611000738921</actrnumber>
  <trial_identification>
    <studytitle>Preventing Nerve Damage Induced by Chemotherapy</studytitle>
    <scientifictitle>A randomised, double-blind, placebo-controlled, cross-over  
study of the effects of calcium and magnesium (Ca Mg) infusions on the pharmacokinetics, motor nerve excitability and acute neurotoxicity symptoms of oxaliplatin, in patients having oxaliplatin chemotherapy for colorectal cancer.</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>The ChAMPION study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Oxaliplatin induced Neurotoxicity</healthcondition>
    <healthcondition>Peripheral neuropathy</healthcondition>
    <healthcondition>Colorectal cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Calcium 1 gm/10 mL and magnesium 1gm/2mL administered simultaneously , or placebo of 5% Dextrose 12mL intravenous infusion, given over 20 minutes, prior to and after chemotherapy on Day1 Cycle 1 and then 21 days later on Day 1 Cycle 2</interventions>
    <comparator>Glucose 5 % intravenous solution, cross-over study</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Intact Oxaliplatin parameters. A HPLC-tandem mass spectrometry method was developed and validated for the quantitation of intact oxaliplatin in human plasma</outcome>
      <timepoint>13 samples during Day 1 of each of  Cycle 1 and Cycle 2 at pre treatment and 20, 40, 60, 90mins during oxaliplatin infusion, end of infusion and 5, 10, 20, 30, 60, 120, 180 minutes after the end of oxaliplatin infusion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Motor nerve excitability  by electromyography</outcome>
      <timepoint>at Cycle 1 and at Cycle 2 Day 2 - 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Self reported neurotoxicity symptoms and study treatment preference questionnaire</outcome>
      <timepoint>Self reported neurotoxicity symptoms questionnaire once on Cycle 1 and once on Cycle 2 between days 10 -20
Study treatment preference questionnaire on Cycle 2 between days 10 -20</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically proven colorectal cancer, eligible for standard oxaliplatin based chemotherapy, written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pre existing neuropathy, contra indicatins to repeated PK sampling or EMG</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomised controlled trial means that allocation of subjects into different groups (i.e. intervention and control) was random or by a method based on chance by sealed opaque envelopes</concealment>
    <sequence>computerised sequence generation, stratified  2 blocks 
stratification on dose, &lt;100mg /m2 or &gt;100mg/m2 oxaliplatin</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2011</anticipatedstartdate>
    <actualstartdate>20/05/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>5/07/2012</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>5/07/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Mark McKeage</primarysponsorname>
    <primarysponsoraddress>Associate Professor 
Dept of Pharmacology and Clinical Pharmacology.
Faculty of Medical and Health Sciences
auckland University
Private bag 92019
Auckland</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Auckland Medical Research Foundation</fundingname>
      <fundingaddress>Auckland City Hospital 
private bag 110139
Auckland1148</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Auckland City Hospital</othercollaboratorname>
      <othercollaboratoraddress>85 Park Road
Grafton
Private Bag 92024
Auckland 1023</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This clinical trial will use techniques and procedures that we have developed for measuring the plasma concentration of intact oxaliplatin and its motor nerve hyperexcitability to generate new information about the use of CaMg infusions for preventing oxaliplatin neurotoxicity. It will test the hypothesis that CaMg infusions alter the pharmacokinetics of oxaliplatin by increasing the rate of its conversion to reactive intermediates such as Pt(diaminocyclohexane)Cl2 by assessing the pharmacokinetics of intact oxaliplatin in colorectal cancer patients given the drug with and without CaMg infusions. In addition, it will test the hypothesis that CaMg infusions could prevent oxaliplatin neurotoxicity by suppressing its acute peripheral nerve hyperexcitability that will tested by needle electromyography (EMG) after oxaliplatin-based treatment given with and without CaMg infusions.

The primary objective is to evaluate the effect of administration of CaMg infusions on the plasma pharmacokinetics of intact oxaliplatin in patients with colorectal cancer. The primary endpoint is intact oxaliplatin pharmacokinetic parameters, including AUC(0-t last), AUC(0-t infinity), Cmax, t1/2, Cl, Vd and Tss. The secondary objectives are to evaluate the effects of CaMg infusions on the pharmacokinetics of total platinum, motor nerve excitability and acute neurotoxicity symptoms in patients with colorectal cancer given oxaliplatin. Secondary endpoints are total platinum pharmacokinetic parameters (AUC(0-t last), AUC(0-t infinity), Cmax, t1/2, Cl, Vd and Tss), abnormal spontaneous high-frequency motor fibre action potentials and patient-reported neurotoxicity symptoms and study treatment preference post-treatment. Exploratory objectives include determining the feasibility of investigating neurotoxicity biomarkers, and changes in plasma concentration and urinary excretion of calcium, magnesium or oxalate, in colorectal cancer patients given oxaliplatin with or without CaMg infusions.</summary>
    <trialwebsite>None</trialwebsite>
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Y Ethics Committee</ethicname>
      <ethicaddress>PO Box 1031 
Hamilton 3204</ethicaddress>
      <ethicapprovaldate>12/04/2011</ethicapprovaldate>
      <hrec>NTY/11/01/005</hrec>
      <ethicsubmitdate>8/12/2010</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Catherine  Han</name>
      <address>University of Auckland
85 Park Road,
Grafton, 1023</address>
      <phone>+64 (0) 9 373 7599 </phone>
      <fax>+64 (0) 9 373 7927</fax>
      <email>c.han@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Catherine Han</name>
      <address>University of Auckland
85 Park Road,
Grafton, 1023</address>
      <phone>+64 (0) 9 373 7599 </phone>
      <fax />
      <email>c.han@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prashannata Khwaounjoo</name>
      <address>University of Auckland
85 Park Road,
Grafton, 1023</address>
      <phone>+64 9 923 1594</phone>
      <fax>+64 (0)9 923 7584</fax>
      <email>p.khwaounjoo@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Catherine Han</name>
      <address>University of Auckland
85 Park Road,
Grafton, 1023</address>
      <phone>+64 (0) 9 373 7599 </phone>
      <fax />
      <email>c.han@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>